Left icon

Register Now!

Free Membership
for our Partner Institutions
Not in List?
We serve 200+ Institutions with limited Free Accounts or $19.95/1 Yr or $39.95/Lifetime Accounts
Not in List?
  • Search over 1500+ listings for MS, PhD and MD holders
  • Discounted Career Tools customized for life science postgraduates
  • Attend Webinars to expose you to varieties of career paths, experts and peers
  • Be able to join the Bio Careers Blog, where you can ask your career questions and find bloggers going through the same job transitions you are

  • Nature Jobs - Career Editorial - Job Market News
    • Sanofi Approached AstraZeneca PLC's For CEO Role
      Sanofis board reached out to AstraZeneca Plc (AZN) Chief Executive Officer Pascal Soriot to sound out his interest in replacing Chris Viehbacher as CEO, according to people familiar with the situation.

      Soriot, who successfully fought off Pfizer Inc.s $117 billion hostile takeover this year, didnt express interest, said the people, who asked not to be identified commenting on internal...
    • AstraZeneca PLC Wins FDA Approval For Two-In-One Diabetes Pill
      U.S. FDA Approves Once-Daily XIGDUO XR Tablets for Adults with Type 2 Diabetes

      First U.S. approval for once-daily tablet combining SGLT2 inhibitor and metformin HCl extended-release

      WILMINGTON, Del., Oct 30, 2014 (BUSINESS WIRE) -- AstraZeneca AZN, -0.11% today announced that the U.S. Food and Drug Administration has approved once-daily XIGDUO...
    • Boston???s Rhythm Withdraws $86 Million IPO Citing Acquisition Agreement With Actavis
      Rhythm Pharmaceuticals, a clinical-stage biotech developing injectable therapies for gastrointestinal diseases, withdrew its plans for an initial public offering on Wednesday. The company originally filed for an $86 million IPO in late August. Last week, the company announced it had signed an agreement with Actavis (ACT) that granted it the option to acquire Rhythm upon the completion of its Phase...
    • Express Scripts Inc. Says AbbVie's Drug Could Displace Gilead Sciences, Inc.'s Sovaldi On Formulary
      (Reuters) - Pharmacy benefit manager Express Scripts Holding Co said it may quickly change its preferred drug formulary to favor an expected new hepatitis C drug from AbbVie if it is clinically equivalent and less costly than Gilead Science Inc's $84,000 Sovaldi and $94,500 Harvoni treatments.

      Sovaldi, with its price tag of $1,000 a pill, has become a lightning rod in a debate over the high...
    • Bayer AG Hunts For More Deals After Bulking Up Consumer Care
      (Reuters) - Bayer is eyeing further takeover deals after wrapping up the acquisition of Merck & Co. Inc.'s consumer health business, the German drugmaker's chief executive said on Thursday.

      "We are looking to expand our business in the future through both organic growth and acquisitions," CEO Marijn Dekkers said, according to the script of a speech to be held at a media call on the group...
    • Cipla Ltd. Asks Government To Revoke Five Patents Held By Novartis AG
      NEW DELHI: Cipla, India's fifthlargest drugmaker by revenue, has asked the government to revoke five patents that NovartisBSE -0.62 % holds on respiratory drug Onbrez and launched its generic version of indacaterol at a fifth of the price, triggering another confrontation between an Indian generic company and a foreign innovator firm. The domestic drugmaker asked the Department of Industrial Policy...
    • Novo Nordisk A/S More Mindful On Timing Of U.S. Tresiba Launch
      (Reuters) - Novo Nordisk is more cautious in its assessment of when it would launch its Tresiba diabetes drug in the United States, a critical growth driver for the future, according to statements it made in its quarterly report.

      The U.S. Food and Drug Administration (FDA) refused in February 2013 to approve Tresiba, a long-acting insulin drug, until Novo provided additional tests for potential...
    • Arena Pharmaceuticals, Inc. Skimps On Data Disclosure From Weight-Loss Combo Study: Analyst
      Arena Pharmaceuticals (ARNA) provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination. Key heart safety and efficacy data were not disclosed in the company's press release announcing results from a short, proof-of-concept study.

      Obese patients offered the "Bel-phen" combo for 12 weeks did not report higher rates of headache, dizziness, nausea...
    • Sanofi Ousts CEO After Clash Over Strategy

    • Under Immense Pressure, Amgen Outlines Strategy

    Science Careers - Job Market News